Education
About Us
Working with TipRanks
Follow Us
PureTech Health (PRTC)
NASDAQ:PRTC
Earnings Data
Report Date
Aug 27, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-2.04Last Year’s EPS
-1.5Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: 1.71%
|Next Earnings Date:Aug 27, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements such as successful clinical trial results and FDA approval, alongside challenges like market valuation disconnect and funding requirements for future trials.Company Guidance
During the PureTech Health 2024 Year-End Financial Results Conference, key metrics and strategic priorities were discussed, emphasizing the company's financial and clinical achievements. As of March 31, 2025, PureTech reported a cash balance of approximately $339.1 million at the PureTech level, with a consolidated cash position of $339.5 million. The company raised $397.5 million in 2024, with over 88% from third-party investors, and generated $327.4 million from monetization events. PureTech returned $100 million to shareholders through a tender offer, showcasing robust financial execution. The guidance highlighted the successful Phase 2b trial of deupirfenidone for IPF, with plans to discuss a Phase 3 trial with the FDA by Q3 2025. PureTech's hub-and-spoke R&D model, known for its capital efficiency, was credited for enabling these developments. The company aims to address the value disconnect in its market valuation by exploring various strategic options, including potential transactions and additional capital return opportunities, to align its valuation with the intrinsic value of its assets and track record of execution.Successful Phase 2b Trial of Deupirfenidone
PureTech announced unprecedented results from the successful Phase 2b trial of deupirfenidone for Idiopathic Pulmonary Fibrosis (IPF), demonstrating significant slowing of lung function decline over at least 26 weeks with a favorable tolerability profile. The trial showed a 50% greater effect size compared to placebo.
FDA Approval of COBENFY
COBENFY, invented at PureTech for the treatment of schizophrenia in adults, was approved by the FDA, marking a significant advance for patients and validation of PureTech's scientific foundation.
Strong Financial Position and Capital Efficiency
As of March 31, 2025, PureTech had approximately $339.1 million in cash, cash equivalents, and short-term investments, enabling the company to maintain financial discipline and strategic flexibility.
LYT-200 Clinical Progress
Strong Phase 1b trial data for LYT-200 in AML and solid tumors, with positive results including six complete responses in a highly pretreated population.
PRTC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PRTC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2025 | $17.50 | $17.26 | -1.37% |
Aug 28, 2024 | $25.00 | $23.50 | -6.00% |
Apr 25, 2024 | $27.48 | $27.86 | +1.38% |
Aug 29, 2023 | $23.50 | $23.80 | +1.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PureTech Health (PRTC) report earnings?
PureTech Health (PRTC) is schdueled to report earning on Aug 27, 2025, TBA Not Confirmed.
What is PureTech Health (PRTC) earnings time?
PureTech Health (PRTC) earnings time is at Aug 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PRTC EPS forecast?
PRTC EPS forecast for the fiscal quarter 2025 (Q2) is -2.04.